What is claimed is:

1. Use of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) in the manufacture of a medicament for ~~A method of~~ treating pemphigus in a human patient in need thereof, wherein a dose of at least 400 mg of PRN1008 is to be administered ~~comprising administering to the human patient a dose of at least 400 mg of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008)~~ once a day (QD) for at least 14 days.

2. The ~~method~~ use of claim 1, wherein a dose of at least 400 mg of PRN1008 is to be administered ~~comprising administering~~ to the human patient QD ~~a dose of at least 400 mg of PRN1008 QD~~ for 14 to 168 days.

3. The ~~method~~ use of claim 1 or 2, wherein a dose of at least 400 mg of PRN1008 is to be administered ~~comprising administering~~ to the human patient ~~a dose of at least 400 mg of PRN1008~~ QD for 14 days.

4. The ~~method~~ use of claim 1 or 2, wherein a dose of at least 400 mg of PRN1008 is to be administered ~~comprising administering~~ to the human patient ~~a dose of at least 400 mg of PRN1008~~ QD for 28 days.

5. The ~~method~~ use of claim 1 or 2, wherein a dose of at least 400 mg of PRN1008 is to be administered~~comprising administering~~ to the human patient ~~a dose of at least 400 mg of PRN1008~~ QD for 84 days.

6. The ~~method~~ use of claim 1 or 2, wherein a dose of at least 400 mg of PRN1008 is to be administered~~comprising administering~~ to the human patient ~~a dose of at least 400 mg of PRN1008~~ QD for 168 days.

7. The ~~method~~ use of claim 1, wherein a dose of 400 mg of PRN1008 is to be administered~~comprising administering~~ to the human patient ~~a dose of 400 mg of PRN1008~~ QD for at least 14 days.

8. The ~~method~~ use of claim 1 or 7, wherein a dose of 400 mg of PRN1008 is to be administered~~comprising administering~~ to the human patient ~~a dose of 400 mg of PRN1008~~ QD for 14 to 168 days.

9. The ~~method~~ use of any of claims 1, 7, or 8, wherein a dose of 400 mg of PRN1008 is to be administered~~comprising administering~~ to the human patient ~~a dose of 400 mg of PRN1008~~ QD for 14 days.

10. The ~~method~~ use of any of claims 1, 7, or 8, wherein a dose of 400 mg of PRN1008 is to be administered~~comprising administering~~ to the human patient ~~a dose of 400 mg of PRN1008~~ QD for 28 days.

11. The ~~method~~ use of any of claims 1, 7, or 8, wherein a dose of 400 mg of PRN1008 is to be administered~~comprising administering~~ to the human patient ~~a dose of 400 mg of PRN1008~~ QD for 84 days.

12. The ~~method~~ use of any of claims 1, 7, or 8, wherein a dose of 400 mg of PRN1008 is to be administered~~comprising administering~~ to the human patient ~~a dose of 400 mg of PRN1008~~ QD for 168 days.

13. The ~~method~~ use of claim 1, ~~comprising~~wherein:

a first dose of 400 mg of PRN1008 is to be administered ~~administering~~ to the human patient ~~a first dose of 400 mg of PRN1008~~ QD for 14 days; and

a second dose of 400 mg of PRN1008 is to be administered~~administering~~ to the human patient ~~a second dose of 400 mg of PRN1008~~ twice a day (BID) for at least 14 days following the administration of the first dose.

14. The ~~method~~ use of claim 13, wherein ~~comprising administering to the human patient~~ a second dose of 400 mg of PRN1008 is to be administered to the human patient BID for 14 to 154 days following the administration of the first dose.

15. The ~~method~~ use of claim 1, ~~comprising~~wherein:

a first dose of 400 mg of PRN1008 is to be administered ~~administering~~ to the human patient ~~a first dose of 400 mg of PRN1008~~ QD for 14 days; and

a second dose of 400 mg of PRN1008 is to be administered ~~administering~~ to the human patient ~~a second dose of 400 mg of PRN1008~~ twice a day (BID) for 14 days following the administration of the first dose; and

a third dose of 600 mg of PRN1008 is to be administered ~~administering~~ to the human patient ~~a third dose of 600 mg of PRN1008~~ BID following the administration of the second dose.

16. The ~~method~~ use of claim 15, wherein a third dose of 600 mg of PRN1008 BID is to be administered ~~comprising administering~~ to the human patient ~~a third dose of 600 mg of PRN1008 BID~~ for at most 140 days following the administration of the second dose.

17. The ~~method~~ use of claim 15, wherein a third dose of 600 mg of PRN1008~~comprising administering~~ is to be administered to the human patient ~~a third dose of 600 mg of PRN1008~~ BID for 56 days following the administration of the second dose.

18. Use of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) in the manufacture of a medicament for ~~A method of~~ treating pemphigus in a human patient in need thereof, wherein ~~comprising administering to the human patient~~ a dose of at least 400 mg of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) is to be administered twice a day (BID) for at least 14 days.

19. The ~~method~~ use of claim 18, ~~comprising administering to the human patient~~ wherein a dose of at least 400 mg of PRN1008 is to be administered to the human patient BID for 14 to 84 days.

20. The ~~method~~ use of claim 18 or 19, ~~comprising administering to the human patient~~wherein a dose of at least 400 mg of PRN1008 is to be administered to the human patient BID for 14 days.

21. The ~~method~~ use of claim 18 or 19, ~~comprising administering to the human patient~~wherein a dose of at least 400 mg of PRN1008 is to be administered to the human patient BID for 28 days.

22. The ~~method~~ use of claim 18 or 19, ~~comprising administering to the human patient~~ wherein a dose of at least 400 mg of PRN1008 is to be administered to the human patient BID for 84 days.

23. The ~~method~~ use of claim 18, ~~comprising administering to the human patient~~wherein a dose of 400 mg of PRN1008 is to be administered to be human patient BID for at least 14 days.

24. The ~~method~~ use of claim 18 or 23, ~~comprising administering~~wherein ~~to the human patient~~ a dose of 400 mg of PRN1008 is to be administered to the human patient BID for 14 to 84 days.

25. The ~~method~~ use of any of claims 18, 23, or 24, ~~comprising administering to the human patient~~wherein a dose of 400 mg of PRN1008 is to be administered to the human patient BID for 14 days.

26. The ~~method~~ use of any of claims 18, 23, or 24, ~~comprising administering to the human patient~~wherein a dose of 400 mg of PRN1008 is to be administered to the human patient BID for 28 days.

27. The ~~method~~ use of any of claims 18, 23, or 24, ~~comprising administering to the human patient~~wherein a dose of 400 mg of PRN1008 is to be administered to the human patient BID for 84 days.

28. The ~~method~~ use of claim 18, ~~comprising~~wherein:

~~administering to the human patient~~ a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for at least 14 days; and

~~administering to the human patient~~ a second dose of 500 mg of PRN1008 is to be administered to the human patient BID following the administration of the first dose.

29. The ~~method~~ use of claim 28, ~~comprising administering to the human patient~~wherein a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for 14 to 28 days.

30. The ~~method~~ use of claim 28, ~~comprising administering to the human patient~~wherein a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for more than 28 days.

31. The ~~method~~ use of claim 28, ~~comprising administering to the human patient~~wherein a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for 33 days.

32. The ~~method~~ use of any of claims 28-31, wherein PRN1008 is to be administered to the human patient for at most 84 days.

33. The ~~method~~ use of claim 18, ~~comprising~~wherein:

~~administering to the human patient~~ a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for at least 14 days; and

~~administering to the human patient~~ a second dose of 600 mg of PRN1008 is to be administered to the human patient BID following the administration of the first dose.

34. The ~~method~~ use of claim 33, ~~comprising administering to the human patient~~wherein a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for 14 to 28 days.

35. The ~~method~~ use of claim 33 or 34, ~~comprising administering to the human patient~~wherein a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for 22 days.

36. The ~~method~~ use of claim 33, ~~comprising administering to the human patient~~wherein a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for more than 28 days.

37. The ~~method~~ use of claim 33 or 36, ~~comprising administering to the human patient~~wherein a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for 56 days.

38. The ~~method~~ use of any of claims 33-37, wherein PRN1008 is to be administered to the human patient for at most 84 days.

39. The ~~method~~ use of claim 18, ~~comprising~~wherein:

~~administering to the human patient~~ a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for at least 14 days;

~~administering to the human patient~~ a second dose of 500 mg of PRN1008 is to be administered to the human patient BID for at least 14 days following the administration of the first dose; and

~~administering to the human patient~~ a third dose of 600 mg of PRN1008 is to be administered to the human patient BID following the administration of the second dose.

40. The ~~method~~ use of claim 39, ~~comprising administering to the human patient~~wherein a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for 14 to 28 days.

41. The ~~method~~ use of claim 39 or 40, ~~comprising administering to the human patient~~wherein a second dose of 500 mg of PRN1008 is to be administered to the human patient BID for 14 to 28 days following the administration of the first dose.

42. The ~~method~~ use of any of claims 39-41, wherein PRN1008 is to be administered to the human patient for at most 84 days.

43. The ~~method~~ use of any of claims 1-42, ~~comprising administering~~wherein PRN1008 is to be administered in combination with a first corticosteroid at a dose of less than or equal to 0.5 mg/kg/day.

44. The ~~method~~ use of claim 43, wherein the first corticosteroid is chosen from prednisone, prednisolone, and methylprednisolone.

45. The ~~method~~ use of any of claims 1-44, wherein the human patient is characterized by naïve or relapsing pemphigus prior to the administration of PRN1008.

46. The ~~method~~ use of any of claims 1-45, wherein the human patient is characterized by naïve or relapsing pemphigus vulgaris prior to the administration of PRN1008.

47. The ~~method~~ use of any of claims 1-46, wherein the human patient is characterized by naïve or relapsing pemphigus foliaceus prior to the administration of PRN1008.

48. The ~~method~~ use of any of claims 1-47, wherein the human patient is characterized by a pemphigus disease activity index (PDAI) skin score from 8 points to 60 points prior to the administration of PRN1008.

49. The ~~method~~ use of any of claims 1-48, wherein the human patient is characterized by a maintenance dose of less than or equal to 0.5 mg/kg/day of a second corticosteroid prior to the administration of PRN1008.

50. The ~~method~~ use of claim 49, wherein the second corticosteroid is chosen from prednisone, prednisolone, and methylprednisolone.

51. The ~~method~~ use of claim 49 or 50, wherein the first corticosteroid is the same as the second corticosteroid.

52. The ~~method~~ use of claim 49 or 50, wherein the first corticosteroid is not the same as the second corticosteroid.

53. The ~~method~~ use of any of claims 1-52, wherein PRN1008 comprises the (E) isomer of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile.

54. The ~~method~~ use of any of claims 1-52, wherein PRN1008 comprises the (Z) isomer of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile.

55. The ~~method~~ use of any of claims 1-52, wherein PRN1008 comprises a mixture of (E) and (Z) isomers of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile.

56. The ~~method~~ use of any of claims 1-55, wherein the medicament is for ~~comprising~~ treating pemphigus vulgaris.

57. The ~~method~~ use of any of claims 1-55, ~~comprising~~ wherein the medicament is for treating pemphigus foliaceus.

58. The ~~method~~ use of any of claims 1-57, ~~comprising~~ wherein the medicament is for reducing average daily corticosteroid usage by the human patient.

59. The ~~method~~ use of claim 58, ~~comprising~~ wherein the medicament is for reducing average daily corticosteroid usage by the human patient by at least 20%.

60. The ~~method~~ use of claim 58, wherein the medicament is for~~comprising~~ reducing average daily corticosteroid usage by the human patient by at least 50%.

61. The ~~method~~ use of any of claims 1-60, ~~comprising~~ wherein the medicament is for healing established pemphigus lesions.

62. The ~~method~~ use of claim 61, wherein the medicament is for~~comprising~~ healing at least 50% of established pemphigus lesions.

63. The ~~method~~ use of any of claims 1-62, wherein the medicament is for~~comprising~~ preventing new pemphigus lesion formation.

64. The ~~method~~ use of any of claims 1-63, wherein the medicament is for~~comprising~~ reducing a pemphigus disease activity index (PDAI) skin score.

65. The ~~method~~ use of claim 64, wherein the medicament is for~~comprising~~ reducing a PDAI skin score by at least 20%.

66. The ~~method~~ use of any of claims 1-64, wherein the human patient is characterized by a pemphigus disease activity index (PDAI) skin score of 0 or 1 following the administration of PRN1008.

67. The ~~method~~ use of claim 66, wherein the human patient is characterized by a PDAI skin score of 0 following the administration of PRN1008.

68. The ~~method~~ use of claim 66, wherein the human patient is characterized by a PDAI skin score of 1 following the administration of PRN1008.

69. The ~~method~~ use of any of claims 1-60, wherein the medicament is for ~~further comprising~~ achieving a control of disease activity of pemphigus.

70. The ~~method~~ use of any of claims 1-60, wherein the medicament is for~~further comprising~~ achieving an end of consolidation phase of pemphigus.

71. The ~~method~~ use of claim 70, wherein more than 60% of established pemphigus lesions have healed.

72. The ~~method~~ use of any of claims 1-60, wherein the medicament is for~~comprising~~ achieving complete remission.

73. The ~~method~~ use of any of claims 1-72, wherein PRN1008 is to be orally administered to the human patient.

74. The ~~method~~ use of any of claims 1-73, wherein PRN1008 is to be administered to the human patient in the form of at least one tablet.

75. The ~~method~~ use of claim 74, wherein PRN1008 is to be administered with a glass of water.

76. The ~~method~~ use of any of claims 1-75, wherein PRN1008 is to be administered with food.

77. The ~~method~~ use of any of claims 1-75, wherein PRN1008 is to be administered without food.